Abstract
Left ventricular hypertrophy (LVH) regression is an important issue in hypertensive patients. Patients with LVH who had received the angiotensin receptor blocker (ARB) treatment for 8 weeks and had not reached the target blood pressure level were enrolled in the study. Patients were assigned to either losartan (50 mg)/hydrochlorothiazide (HCTZ, 12.5 mg) group or ARB + CCB group (usual dose of ARB and calcium channel blocker, CCB). After 48 weeks, LV mass index was found to be reduced significantly in the losartan/HCTZ group but not in the ARB + CCB group. These results suggest that combination therapy of an ARB and diuretic has greater potential to cause regression compared with an ARB and CCB.
Publication types
-
Comparative Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Angiotensin Receptor Antagonists / therapeutic use*
-
Blood Pressure
-
Calcium Channel Blockers / therapeutic use*
-
Diuretics / administration & dosage
-
Diuretics / therapeutic use*
-
Drug Therapy, Combination / methods
-
Echocardiography
-
Female
-
Humans
-
Hydrochlorothiazide / administration & dosage
-
Hydrochlorothiazide / therapeutic use*
-
Hypertension / complications
-
Hypertension / drug therapy*
-
Hypertrophy, Left Ventricular / complications
-
Hypertrophy, Left Ventricular / diagnostic imaging
-
Hypertrophy, Left Ventricular / drug therapy*
-
Losartan / therapeutic use*
-
Male
-
Middle Aged
-
Treatment Outcome
Substances
-
Angiotensin Receptor Antagonists
-
Calcium Channel Blockers
-
Diuretics
-
Hydrochlorothiazide
-
Losartan